Search

The potential neuroprotective action of the corticotrophin-releasing factor-related peptide urocortin (UCN) was investigated in the rat 6-hydroxydopamine (6-OHDA) and lipopolysaccharide (LPS) paradigms of Parkinson's disease. UCN (20 fmol) was either given at the same time as (T = 0) or 7 days after (T = +7) intracerebral 6-OHDA or LPS injection. At 14 days after 6-OHDA or LPS injection, circling behaviour was measured following apomorphine challenge. Circling was significantly lower in rats given UCN at either T = 0 or T = +7 compared with animals given 6-OHDA or LPS and vehicle. Sham-treated rats showed no circling. Consistent with these observations, striatal dopamine concentrations were markedly higher in 6-OHDA/LPS + UCN rats vs. 6-OHDA/LPS + vehicle groups. Additionally, L-dihydroxyphenylalanine production by tyrosine hydroxylase was greatly reduced in the striata of 6-OHDA/LPS + vehicle rats, whereas this was not the case in rats coadministered UCN. Finally, the numbers of tyrosine hydroxylase-positive cells recorded in the substantia nigra of 6-OHDA/LPS + vehicle-treated animals were markedly lower than those of sham-operated or 6-OHDA/LPS + UCN rats. Critically, UCN was effective in reversing lesion-induced deficits when given either at the same time as or 7 days after the neurotoxic insult. To our knowledge, this is the first time that such an effect has been demonstrated in vivo. The apparent ability of UCN to arrest the progression of or even reverse nigral lesions once established suggests that pharmacological manipulation of this system could have substantial therapeutic utility.

We have investigated the effects of glucocorticoid manipulation on corticotrophin-releasing factor (CRF-41) in the neurointermediate lobe (NIL) and median eminence (ME) of the rat using a radioimmunoassay specific for CRF-41. CRF-41 content in the NIL (88+/-7 fmol, mean +/- SEM) was not significantly altered by administration of dexamethasone in drinking water for 12 days (67+/-9 fmol) or adrenalectomy for 12 days (96+/-17 fmol). The saline-stimulated increase in NIL CRF-41 content (154+/-24 fmol) was not affected by dexamethasone (152+/-24 fmol) or adrenalectomy (179+/-21 fmol). In contrast, the content of CRF-41 in the ME declined following dexamethasone treatment (1247+/-92 fmol to 864+/-26 fmol), or adrenalectomy (854+/-78 fmol). Our results provide further evidence that CRF-41 in the NIL and ME can be differentially regulated.